Categories AlphaGraphs, Earnings, Health Care
Johnson & Johnson (JNJ) Q2 2024 Earnings: Key financials and quarterly highlights
Johnson & Johnson (NYSE: JNJ) reported its second quarter 2024 earnings results today.
Reported sales increased 4.3% year-over-year to $22.4 billion. Operational sales growth was 6.6%.
Net income decreased 12.8% to $4.6 billion while EPS dropped 5.9% to $1.93. Adjusted EPS rose 10.2% to $2.82.
Revenue and earnings beat estimates.
For the full year of 2024, JNJ expects reported sales of $88.0-88.4 billion and adjusted EPS of $9.97-10.07.
The stock was down over 1% in premarket hours on Wednesday.
Prior performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
NeOnc Technologies plans to go public through direct listing
NeOnc Technologies Holdings Inc., a privately held clinical-stage biotechnology company that develops therapies to improve the treatment of brain tumors and central nervous system diseases, is preparing to become a
Chewy (CHWY): A few factors that work in favor of this pet supplies retailer
Shares of Chewy, Inc. (NYSE: CHWY) were down over 1% on Tuesday. The stock has gained 72% over the past 12 months. The company delivered sales and earnings growth for
Amazon looks set for another strong year as cloud and ads boom
Taking a cue from the AI frenzy, Amazon.com Inc. (NASDAQ: AMZN) has adopted a growth strategy focused on expanding generative AI capabilities, through initiatives like the recent expansion of its
